Biological markers for therapeutic trials in Alzheimer's disease: Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

Neurobiology of Aging

Volumn 24, Issue 4, 2003, Pages 521-536

  Frank, Richard A ^a   Galasko, Douglas ^b   Hampel, Harald ^c   Hardy, John ^d   De Leon, Mony J ^e   Mehta, Pankaj D ^f   Rogers, Joseph ^g   Siemers, Eric ^h   Trojanowski, John Q ⁱ  

^a PFIZER INC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^g SUN HEALTH RESEARCH INSTITUTE   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Bioassay; Biomarkers; Blood; CSF; Dementia; Diagnostics; Disease modification; Drug development; Enrichment strategy; Mild cognitive impairment (MCI); Prognostics; Progression; Screening; Surrogate endpoints

Indexed keywords

3 NITROTYROSINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD59 ANTIGEN; CHYMOTRYPSIN INHIBITOR; COMPLEMENT COMPONENT C1Q; DNA; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GLYCOPROTEIN GP 130; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPROSTANE; KALLIKREIN; MELANOTRANSFERRIN; NEUROFILAMENT PROTEIN; OXYSTEROL; PROTEIN S100B; RNA; SULFATIDE; TAU PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN B GROUP;

AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BLOOD VESSEL INJURY; CEREBROSPINAL FLUID ANALYSIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DENSITOMETRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ELECTROCHEMICAL DETECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; GAS CHROMATOGRAPHY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOBLOTTING; LIPID PEROXIDATION; MASS SPECTROMETRY; MEMORY DISORDER; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PAIRED HELICAL FILAMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; RISK FACTOR; SIGNAL TRANSDUCTION; SYMPTOM; URINALYSIS; VITAMIN BLOOD LEVEL;

EID: 0037411512     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00002-2     Document Type: Article

References (166)

1. Abraham C.R., Selkoe D.J., Potter H. Immunochemical identification of serine protease inhibitor alfa-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501.
2. Adelman R., Saul R.L., Ames B.N. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc. Natl. Acad. Sci. 85:1988;2706-2708.
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M.et al. [The Neuroinflammation Working Group]. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21(3):2000;383-421.
4. Andreasen M., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B.et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch. Neurol. 56:1999;673-680.
5. Andreasen M., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B.et al. Evaluation for CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58:2001;373-379.
6. Andreasen M., Minthon L., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273:1999;5-8.
7. Aoyama K., Matsubara K., Fujikawa Y., Nagahiro Y., Shimizu K., Umegae N.et al. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann. Neurol. 47:2000;524-527.
8. Auer J., Rammer M., Berent R., Weber T., Lassnig E., Eber B. Relation of C-reactive protein levels to presence, extent, and severity of angiographic coronary artery disease. Indian Heart J. 54:2002;284-288.
9. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
10. Baskin F., Rosenberg R.N., Iyer L., Hynan L., Cullum C.M. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology. 54:2000;1907-1909.
11. Bayer T.A., Wirths O., Majtenyi K., Hartmann T., Multhaup G., Beyreuther K.et al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 11:2001;1-11.
12. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta1-42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24:2001;87-97.
13. Bogdanov M., Beal M.F., McCabe D.R., Griffin R.M., Matson W.R. A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2-deoxyguanosine measurements in urine and other biologic matrices: a 1-year evaluation of methods. Free Radic. Biol. Med. 27:1999;647-666.
14. Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O'Donnell H.et al. Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 29:2000;652.
15. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
16. Brachova L., Lue L.F., Schultz J., el Rashidy T., Rogers J. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Mol. Brain Res. 18:1993;329-334.
17. Bretillon L., Siden A., Wahlund L.O., Lutjohann D., Minthon L., Crisby M.et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci. Lett. 293:2000;87-90.
18. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M.et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41:1997;646-653.
19. Bürger K., Padberg F., Nolde T., Stübner S., Teipel S.J., Haslinger A.et al. CSF tau protein discriminates between Alzheimer's disease, major depression and healthy controls in young old, but not in old old. Neurosci. Lett. 277(1):1999;21-24.
20. Bürger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R.et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59(4):2002;627.
21. Bürger K., Zinkowski R., Teipel S.J., Arai H., DeBernardis J., Kerkman D.et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am. J. Psychiatr. 160:2003;376-379.
22. Bürger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K.et al. Differential diagnosis of Alzheimer's diesease with CSF tau protein phosphorylated at threonine 231. Arch. Neurol. 59(8):2002;1267-1272.
23. Bush A.I., Martins R.N., Rumble B., Moir R., Fuller S., Milward E.et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. Biol. Chem. 265:1990;15977-15983.
24. Clarke R., Collins R. Can dietary supplements with folic acid or Vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J. Cardiovasc. Risk. 5:1998;249-255.
25. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M. Folate, Vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55:1998;1449-1455.
26. Davidsson P., Puchades M., Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 20:1999;431-437.
27. de la Monte S.M., Volicer L., Hauser S.L., Wands J.R. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 32:1992;733-742.
28. de la Monte S.M., Xu Y.Y., Wands J.R. Modulation of neuronal thread protein expression with neuritic sprouting: relevance to Alzheimer's disease. J. Neurol. Sci. 138:1996;26-35.
29. de Leon M.J., Segal C.Y., Tarshish C.Y., de Santi S., Zinkowski R., Mehta P.D.et al. Longitudinal CSF tau load increases in mild cognitive impairment. Neurosci. Lett. 333:2002;183-186.
30. Diamandis E.P., Yousef G.M., Petraki C., Soosaipillai A.R. Human Kallikrein 6 as a biomarker of Alzheimer's disease. Clin. Biochem. 33:2000;663-667.
31. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Grass L., Porter A., Little S.et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin. Biochem. 33:2000;369-375.
32. Di Luca M., Pastorino L., Bianchetti A., Perez J., Vignolo L.A., Lenzi G.L.et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch. Neurol. 55:1998;1195-2000.
33. Di Luca M., Pastorino L., Cattabeni F., Zanardi R., Scarone S., Racagni G.et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch. Neurol. 53:1996;1162-1166.
34. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim. Biophys. Acta. 1450:1999;191-231.
35. Du Y., Dodel R., Hampel H., Bürger K., Lin S., Eastwood B.et al. Reduced CSF levels of amyloid-beta peptide antibody in Alzheimer's disease. Neurology. 57:2001;801-805.
36. Dzeletovic S., Breuer O., Lund E., Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225:1995;73-80.
37. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
38. Fang Q., Kannapell C.C., Fu S.M., Xu S., Gaskin F. VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains. Clin. Immunol. Immunopathol. 75:1995;159-167.
39. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P.et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5856-5861.
40. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S.et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 59:2002;1257-1258.
41. Feldman H., Gabathuler R., Kennard M., Nurminen J., Levy D., Foti S.et al. Serum p97 levels as an aid to identifying Alzheimer's disease. J. Alzheimer Dis. 3:2001;507-516.
42. Ferrante R.J., Browne S.E., Shinobu L.A., Bowling A.C., Baik M.U., MacGarvey U.et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69:1997;2064-2074.
43. Gabbita S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71:1998;2034-2040.
44. Galasko D., Hansen L.A., Katzman R., Wiederholt W., Masliah E., Terry R.et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 51:1994;888-895.
45. Gaskin F., Finley J., Fang Q., Xu S., Fu S.M. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J. Exp. Med. 177:1993;1181-1186.
46. Giasson B.I., Lee V.M-Y., Ischiropoulos H., Trojanowski J.Q. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's disease. Free Radic. Biol. Med. 32:2002;1264-1275.
47. Giasson B.I., Lee V.M-Y., Ischiropoulos H., Trojanowski J.Q. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's disease. Free Radic. Biol. Med. 32:2002;1264-1275.
48. Green A.J., Harvey R., Thompson E., Rossor M. Increased S100 beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci. Lett. 235:1997;5-8.
49. Growdon J.H., Selkoe D.J., Roses A., Trojanowski J.Q., Davies P., Appel S.et al. [Working Group Advisory Committee]. Consensus report of the Working Group on Biological Markers of Alzheimer's Disease. [Ronald and Nancy Reagan Institute of the Alzheimer's Association and National Institute on Aging Working Group on Biological Markers of Alzheimer's Disease]. Neurobiol. Aging. 19:1998;109-116.
50. Hampel H., Bürger K., Kohnken R., Teipel S.J., Zinkowski R., Möller H.J.et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49(4):2001;545-546.
51. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Andreasen N, Sjogren M, et al. Detection of different phosphorylated epitopes of CSF tau protein in the differential diagnosis of AD - a comparative study. Arch Gen Psychiatr (accepted).
52. Hampel H, Scheloske M, Haslinger A. The interleukin-6 receptor complex. In: Rogers J, editor. Neuroinflammatory mechanisms in Alzheimer's disease: basic and clinical research. Basel, Switzerland: Birkhäuser Publishers; 2001. p. 121-43.
53. Hampel H., Schoen D., Schwarz M.J., Kötter H.U., Schneider C., Sunderland T.et al. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 228:1997;143-146.
54. Hampel H., Sunderland T., Kötter H.U., Schneider C., Dukoff R., Levy J.et al. Decreased soluble interleukin-6 receptor in CSF of patients with Alzheimer's disease. Brain Res. 780(2):1998;351-354.
55. Hampel H, Teipel SJ, Faltraco F, Brettschneider S, Goernitz A, Buerger K, et al. Advances in the development of biomarkers for Alzheimer's disease - from CSF total tau and Abeta1-42 proteins to phosphorylated tau and amyloid-beta-antibodies. In: Takeda M, editor. Molecular neurobiology of Alzheimer's disease and related disorders. Tokio: Karger Publishers; 2003, in press.
56. Hampel H., Teipel S.J., Padberg F., Haslinger A., Riemenschneider M., Schwarz M.J.et al. Discriminant power of combined cerebrospinal fluid tau protein and soluble gp130 in the diagnosis of Alzheimer's disease. Brain Res. 823(1-2):1999;104-112.
57. Han X., Holtzman D.M., McKeel D.W., Kelly J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82:2002;809-818.
58. Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 24(Suppl. 11):2001;S45-S48.
59. Henriksson T., Barbour R.M., Braa S., Ward P., Fritz L.C., Johnson-Wood K.et al. Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J. Neurochem. 56:1991;1037-1042.
60. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosien in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 18:1998;8126-8132.
61. Hensley K., Williamson K.S., Floyd R. Measurement of 3-nitrotyrosine and 5-nitro-α-tocopherol by high-performance liquid chromatography with electrochemical detection. Free Radic. Biol. Med. 28:1999;520-528.
62. Holtzman D.M., Fagan A.M., Han X. CSF sulfatide levels: a possible biomarker for Alzheimer's disease at the earliest clinical stages. Neurology. 58(Suppl. 3):2002;A361.
63. Hu Y.Y., He S.S., Wang X.C., Duan Q.H., Khatoon S., Iqbal K.et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320:2002;156-160.
64. Hulstaeert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P.et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology. 52:1999;1555-1562.
65. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X.et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann. Neurol. 49:2001;808-810.
66. Inoue S., Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett. 371:1995;86-88.
67. Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H.et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 50:2001;150-156.
68. Jellinger K.A. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol. 91:1996;219-220.
69. Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N.et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 45:1999;504-511.
70. Kahle P.J., Jakowec M., Teipel S.J., Hampel H., Petzinger G.M., Di Monte D.A.et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 54:2000;1498-1504.
71. Kennard M.L., Feldman H., Yamada T., Jefferies W.A. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat. Med. 2:1996;1230-1235.
72. Kim D.K., Seo M.Y., Lim S.W., Kim S., Kim J.W., Carroll B.J.et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology. 25:2001;84-90.
73. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J.et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 287:2000;187-190.
74. Kotzbauer P.T., Trojanowski J.Q., Lee V.M-Y. Lewy body pathology in Alzheimer's disease. J. Mol. Neurosci. 17:2001;225-232.
75. Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: IL-1beta, IL-6, IL-1 receptor antagonist, TNF-alpha, the soluble TNF receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12:1998;215-227.
76. Licastro F., Morini M.C., Polazzi E., Davis L.J. Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 57:1995;71-75.
77. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C.et al. Increased plasma levels of IL-1, IL-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103:2000;97-102.
78. Licastro F., Pedrini S., Davis L.J., Caputo L., Tagliabue J., Savorani G.et al. Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis. Assoc. Disord. 15:2001;51-55.
79. Little S.P., Dixon E.P., Norris F., Buckley W., Becker G.W., Johnson M.et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J. Biol. Chem. 272:1997;25135-25142.
80. Lovell M.A., Gabbita S.P., Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 72:1999;771-776.
81. Lovell M.A., Markesbery W.R. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in the Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 58:2001;392-396.
82. Masliah E. The role of synaptic proteins in Alzheimer's disease. Ann. N Y Acad. Sci. 924:2000;68-75.
83. Matsubara E., Hirai S., Amari M., Shoji M., Yamaguchi H., Okamoto K.et al. Alpha 1-antichymotrysin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. 28:1990;561-567.
84. Mayeux R., Tang M.X., Jacobs D.M., Manly J., Bell K., Merchant C.et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46:1999;412-416.
85. McGeer E.G., Yasojima K., Schwab C., McGeer P.L. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging. 22:2001;843-848.
86. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
87. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 34:1984;939-944.
88. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-751.
89. Mecocci P., Parnetti L., Donato R., Santucci C., Santucci A., Cadini D.et al. Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain Behav. Immun. 6:1992;286-292.
90. Mecocci P., Parnetti L., Romano G., Scarelli A., Chionne F., Cecchetti R.et al. Serum anti-GFAP and anti S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J. Neuroimmunol. 57:1995;165-170.
91. Mehta P.D., Kim K.S., Wisniewski H.M. ELISA as a laboratory test to aid the diagnosis of Alzheimer's disease. Tech. Diagn. Pathol. 2:1991;99-112.
92. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57:2000;100-105.
93. Miller J.W., Green R., Mungas D.M., Reed B.R., Jagust W.J. Homocysteine, Vitamin B6, and vascular disease in AD patients. Neurology. 58:2002;1471-1475.
94. Moller J., Ahola L., Abrahamsson L. Evaluation of the DPC IMMULITE 2000 assay for total homocysteine in plasma. Scand. J. Clin. Lab. Invest. 62:2002;369-373.
95. Moller L., Hofer T., Zeisig M. Methodological considerations and factors affecting 8-hydroxy-2-deoxyguanosine analysis. Free Radic. Res. 29:1998;511-524.
96. Monte S.M., Ghanbari K., Frey W.H., Beheshti I., Averback P., Hauser S.L.et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kDa protein in cerebrospinal fluid. J. Clin. Invest. 100:1997;3093-3104.
97. Morris M.S., Jacques P.F., Rosenberg I.H., Selhub J. National health and nutrition examination survey. Hyperhomocysteinemia associated with poor recall in the third national health and nutrition examination survey. Am. J. Clin. Nutr. 73:2001;927-933.
98. Motter R., Vigo-Pelfrey C., Khodolenko D., Barbour R., Johnson-Wood K., Galasko D.et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer disease. Ann. Neurol. 38:1995;643-648.
99. Mrak R.E., Sheng J.G., Griffin W.S. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55:1996;273-279.
100. Munzar M., Levy S., Rush R., Averback P. Clinical study of a urinary competitve ELISA for neural thread protein in Alzheimer disease. Neurol. Clin. Neurophysiol. 1:2002;2-8.
101. Murray I.V.J., Lee V.M-Y., Trojanowski J.Q. Synucleinopathies: a pathological and molecular review. Clin. Neurosci. Res. 1/6:2001;445-455.
102. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P.et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 17:1998;14-20.
103. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230-236.
104. Padovani A., Borroni B., Colciaghi F., Pettenati C., Cottini E., Agosti C.et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch. Neurol. 59:2002;71-75.
105. Palmert M.R., Usiak M., Mayeux R., Raskind M., Tourtellotte W.W., Younkin S.G. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology. 40:1990;1028-1034.
106. Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R.et al. 4S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36:2002;27-32.
107. Peskind E.R., Griffin W.S., Akama K.T., Raskind M.A., Van Eldik L.J. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem. Int. 39:2001;409-413.
108. Pirttila T., Mehta P.D., Frey H., Wisniewski H.M. Alpha 1-antichymotrypsin, and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging. 15:1994;313-317.
109. Pirttila T., Mehta P.D., Soininen H., Kim K.S., Heinonen O., Paljarvi L.et al. Cerebrospinal fluid concentrations of soluble amyloid β-protein and apolipoprotein e in patients with Alzheimer's disease. Arch. Neurol. 53:1996;189-193.
110. Pratico D. Alzheimer's disease and oxygen radicals: new insights. Biochem. Pharmacol. 63:2002;563-567.
111. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., FitzGerald G.A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48:2000;809-812.
112. Pratico D., Clark C.M., Liun F., Lee V.M-Y., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impaiment: a possible predictor of Alzheimer's disease. Arch. Neurol. 59:2002;972-976.
113. Pratico D., Uru K., Leight S., Trojanowski J.Q., Lee V.M-Y. Increased lipid peroxidation precedes brain deposition of Aβ in a transgenic mouse model of Alzheimer's disease amyloidosis. J. Neurosci. 21:2001;4183-4187.
114. Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T.et al. Acyl-coenzyme a: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3:2001;905-912.
115. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T.et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:2001;890-899.
116. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
117. Rifai N. C-reactive protein and coronary heart disease. Cardiovasc. Toxicol. 1:2001;153-157.
118. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D.et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10016-10020.
119. Romas S.N., Tang M.X., Berglund L., Mayeux R. Apo E genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology. 53:1999;517-521.
120. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 67:1996;2013-2018.
121. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology. 52:1999;1090-1093.
122. Sanchez-Ramos J.R., Overnuik E., Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration. 3:1994;197-204.
123. Saunders A.M., Strittmatter W.J., Schmechel D., St. George-Hyslop P.H., Pericak-Vance M.A., Joo S.H.et al. Association of apolipoprotein E allele E$ with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
124. Schenk D.B., Seubert P., Lieberburg I., Wallace J. Amyloid beta-peptide immunization: a possible new treatment for Alzheimer disease. Arch. Neurol. 57:2000;934-936.
125. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N.et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
126. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann. Neurol. 52:2002;168-174.
127. Schönknecht P, Pantel J, Hunt A, Volkmann M, Buerger K, Hampel H, et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett, in press.
128. Selkoe D. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:1994;489-517.
129. Sennvik K., Fastbom J., Blomberg M., Wahlund L.O., Winblad B., Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 278:2000;169-172.
130. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B.et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346:2002;476-483.
131. Shen Y., Li R., McGeer E.G., McGeer P.L. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769:1997;391-395.
132. Shen Y., Lue L., Yang L., Roher A., Kuo Y., Strohmeyer R.et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305:2001;165-168.
133. Sheng J.G., Mrak R.E., Rovnaghi C.R., Kozlowska E., Van Eldik L.J., Griffin W.S. Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiol. Aging. 17:1996;359-363.
134. Siest G., Bertrand P., Qin B., Herbeth B., Serot J.M., Mansana L.et al. Apolipoprotein E polymorphism, and serum concentration in Alzheimer's disease in nine European centres: the Apo Europe group. Clin. Chem. Lab. Med. 38:2000;721-730.
135. Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J.et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52:2002;346-350.
136. Sjogren M., Blomberg M., Jonsson M., Wahlund L.O., Edman A., Lind K.et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 66:2001;510-516.
137. Sjogren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelso C.et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg Psychiatr. 70:2001;624-630.
138. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 54:2000;1960-1964.
139. Slooter A.J., de Knijff P., Hofman A., Cruts M., Breteler M.M., Van Broeckhoven C.et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci. Lett. 248:1998;21-24.
140. Smyth M.D., Cribbs D.H., Tenner A.J., Shankle W.R., Dick M., Kesslak J.P.et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging. 15:1994;609-614.
141. Sparks D.L., Kuo Y.M., Roher A., Martin T., Lukas R.J. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observation. Ann. N Y Acad. Sci. 903:2000;335-344.
142. Taddei K., Clarnette R., Gandy S.E., Martins R.N. Increased plasma apolipoprotein E (Apo E) levels in Alzheimer's disease. Neurocsi. Lett. 223:1997;29-32.
143. Takahashi M., Stanton E., Moreno J.I., Jackowski G. Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias. Clin. Chem. 48:2002;375-378.
144. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y.et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer disease. J. Neurol. Sci. 141:1996;65-68.
145. Tamaoka A., Sawamura N., Fukushima T., Shoji M., Hirai S., Furiya Y.et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer disease. J. Neurol. Sci. 148:1997;41-45.
146. Tanaka J., Nakamura K., Takeda M., Tada K., Suzuki H., Morita H.et al. Enzyme-linked immunosorbent assay for human autobody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease. Acta Neurol. Scand. 80:1989;554-560.
147. Tapiola T., Pirttila T., Mikkonen M., Mehta P.D., Alafuzoff I., Koivisto K.et al. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 280:2000;119-122.
148. Terryberry J.W., Thor G., Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging. 19:1998;205-216.
149. Teunissen C.E., de Vente J., Steinbusch H.W.M., De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging. 23:2002;485-508.
150. Tierney M.C., Fisher R.H., Lewis A.J.et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology. 38:1988;359-364.
151. Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci. Lett. 269:1999;53-54.
152. Trojanowski J.Q., Lee V.M-Y. Brain degeneration linked to "fatal attractions" of proteins in Alzheimer's disease and related disorders. J. Alzheimer Dis. 3:2001;117-119.
153. Tumani H., Shen G., Peter J.B., Bruck W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? Arch. Neurol. 56(10):1999;1241-1246.
154. Vanderstichele H., Van Kerchaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N.et al. Standardization of measurement of β-amyloid (1-42) in cerebrospinal fluid and plasma. Int. J. Exp. Clin. Invest. 7:2000;245-258.
155. Van Eldik L.J., Griffin W.S.T. S100β expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim. Biophys. Acta. 1223:1994;398-403.
156. Van Nostrand W.E., Wagner S.L., Shankle W.R., Farrow J.S., Dick M., Rozemuller J.M.et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl. Acad. Sci. U.S.A. 89:1992;2551-2555.
157. Wallin A., Blennow K., Rosengren L.E. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia. 7:1996;267-272.
158. Webster S., Bonnell B., Rogers J. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 150:1997;1531-1536.
159. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K.et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
160. Webster S., Rogers J. Relative efficacies of amyloid beta peptide (Aβ) binding proteins in A beta aggregation. J. Neurosci. Res. 46:1996;58-66.
161. Wisniewski H.M., Wegiel J. The neuropathology of Alzheimer's diseasse. Neuroimaging Clin. N. Am. 5:1995;45-57.
162. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57:2000;1439-1443.
163. Xu S., Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 94:1997;213-222.
164. Yang L.B., Li R., Meri S., Rogers J., Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20:2000;7505-7509.
165. Zarghooni M., Soosaipillai A., Grass L., Scorilas A., Mirazimi N., Diamandis E.P. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin. Biochem. 35:2002;225-231.
166. Zighetti M.L., Chantarangkul V., Tripodi A., Mannucci P.M., Cattaneo M. Determination of total homocysteine in plasma: comparison of the Abbott IMx immunoassay with high performance liquid chromatography. Haematologica. 87:2002;89-94.